A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease

Nalini Raghavachari, Jennifer Barb, Yanqin Yang, Poching Liu, Kimberly Woodhouse, Daniel Levy, Christopher J. Odonnell, Peter J. Munson, Gregory J. Kato

Research output: Contribution to journalArticle

Abstract

Background: Transcriptomic studies in clinical research are essential tools for deciphering the functional elements of the genome and unraveling underlying disease mechanisms. Various technologies have been developed to deduce and quantify the transcriptome including hybridization and sequencing-based approaches. Recently, high density exon microarrays have been successfully employed for detecting differentially expressed genes and alternative splicing events for biomarker discovery and disease diagnostics. The field of transcriptomics is currently being revolutionized by high throughput DNA sequencing methodologies to map, characterize, and quantify the transcriptome. Methods: In an effort to understand the merits and limitations of each of these tools, we undertook a study of the transcriptome in sickle cell disease, a monogenic disease comparing the Affymetrix Human Exon 1.0 ST microarray (Exon array) and Illuminas deep sequencing technology (RNA-seq) on whole blood clinical specimens. Results: Analysis indicated a strong concordance (R = 0.64) between Exon array and RNA-seq data at both gene level and exon level transcript expression. The magnitude of differential expression was found to be generally higher in RNA-seq than in the Exon microarrays. We also demonstrate for the first time the ability of RNA-seq technology to discover novel transcript variants and differential expression in previously unannotated genomic regions in sickle cell disease. In addition to detecting expression level changes, RNA-seq technology was also able to identify sequence variation in the expressed transcripts. Conclusions: Our findings suggest that microarrays remain useful and accurate for transcriptomic analysis of clinical samples with low input requirements, while RNA-seq technology complements and extends microarray measurements for novel discoveries.

Original languageEnglish (US)
Article number28
JournalBMC Medical Genomics
Volume5
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Sickle Cell Anemia
Transcriptome
Exons
RNA
Technology
High-Throughput Nucleotide Sequencing
Alternative Splicing
Genes
Biomarkers
Genome
Research

Keywords

  • Clinical genomics
  • Exon arrays
  • RNA-Seq
  • Sickle cell disease
  • Transcriptome

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease. / Raghavachari, Nalini; Barb, Jennifer; Yang, Yanqin; Liu, Poching; Woodhouse, Kimberly; Levy, Daniel; Odonnell, Christopher J.; Munson, Peter J.; Kato, Gregory J.

In: BMC Medical Genomics, Vol. 5, 28, 2012.

Research output: Contribution to journalArticle

Raghavachari, Nalini ; Barb, Jennifer ; Yang, Yanqin ; Liu, Poching ; Woodhouse, Kimberly ; Levy, Daniel ; Odonnell, Christopher J. ; Munson, Peter J. ; Kato, Gregory J. / A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease. In: BMC Medical Genomics. 2012 ; Vol. 5.
@article{dd0035032b9541ec86372e7a4e40d1f3,
title = "A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease",
abstract = "Background: Transcriptomic studies in clinical research are essential tools for deciphering the functional elements of the genome and unraveling underlying disease mechanisms. Various technologies have been developed to deduce and quantify the transcriptome including hybridization and sequencing-based approaches. Recently, high density exon microarrays have been successfully employed for detecting differentially expressed genes and alternative splicing events for biomarker discovery and disease diagnostics. The field of transcriptomics is currently being revolutionized by high throughput DNA sequencing methodologies to map, characterize, and quantify the transcriptome. Methods: In an effort to understand the merits and limitations of each of these tools, we undertook a study of the transcriptome in sickle cell disease, a monogenic disease comparing the Affymetrix Human Exon 1.0 ST microarray (Exon array) and Illuminas deep sequencing technology (RNA-seq) on whole blood clinical specimens. Results: Analysis indicated a strong concordance (R = 0.64) between Exon array and RNA-seq data at both gene level and exon level transcript expression. The magnitude of differential expression was found to be generally higher in RNA-seq than in the Exon microarrays. We also demonstrate for the first time the ability of RNA-seq technology to discover novel transcript variants and differential expression in previously unannotated genomic regions in sickle cell disease. In addition to detecting expression level changes, RNA-seq technology was also able to identify sequence variation in the expressed transcripts. Conclusions: Our findings suggest that microarrays remain useful and accurate for transcriptomic analysis of clinical samples with low input requirements, while RNA-seq technology complements and extends microarray measurements for novel discoveries.",
keywords = "Clinical genomics, Exon arrays, RNA-Seq, Sickle cell disease, Transcriptome",
author = "Nalini Raghavachari and Jennifer Barb and Yanqin Yang and Poching Liu and Kimberly Woodhouse and Daniel Levy and Odonnell, {Christopher J.} and Munson, {Peter J.} and Kato, {Gregory J.}",
year = "2012",
doi = "10.1186/1755-8794-5-28",
language = "English (US)",
volume = "5",
journal = "BMC Medical Genomics",
issn = "1755-8794",
publisher = "BioMed Central",

}

TY - JOUR

T1 - A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease

AU - Raghavachari, Nalini

AU - Barb, Jennifer

AU - Yang, Yanqin

AU - Liu, Poching

AU - Woodhouse, Kimberly

AU - Levy, Daniel

AU - Odonnell, Christopher J.

AU - Munson, Peter J.

AU - Kato, Gregory J.

PY - 2012

Y1 - 2012

N2 - Background: Transcriptomic studies in clinical research are essential tools for deciphering the functional elements of the genome and unraveling underlying disease mechanisms. Various technologies have been developed to deduce and quantify the transcriptome including hybridization and sequencing-based approaches. Recently, high density exon microarrays have been successfully employed for detecting differentially expressed genes and alternative splicing events for biomarker discovery and disease diagnostics. The field of transcriptomics is currently being revolutionized by high throughput DNA sequencing methodologies to map, characterize, and quantify the transcriptome. Methods: In an effort to understand the merits and limitations of each of these tools, we undertook a study of the transcriptome in sickle cell disease, a monogenic disease comparing the Affymetrix Human Exon 1.0 ST microarray (Exon array) and Illuminas deep sequencing technology (RNA-seq) on whole blood clinical specimens. Results: Analysis indicated a strong concordance (R = 0.64) between Exon array and RNA-seq data at both gene level and exon level transcript expression. The magnitude of differential expression was found to be generally higher in RNA-seq than in the Exon microarrays. We also demonstrate for the first time the ability of RNA-seq technology to discover novel transcript variants and differential expression in previously unannotated genomic regions in sickle cell disease. In addition to detecting expression level changes, RNA-seq technology was also able to identify sequence variation in the expressed transcripts. Conclusions: Our findings suggest that microarrays remain useful and accurate for transcriptomic analysis of clinical samples with low input requirements, while RNA-seq technology complements and extends microarray measurements for novel discoveries.

AB - Background: Transcriptomic studies in clinical research are essential tools for deciphering the functional elements of the genome and unraveling underlying disease mechanisms. Various technologies have been developed to deduce and quantify the transcriptome including hybridization and sequencing-based approaches. Recently, high density exon microarrays have been successfully employed for detecting differentially expressed genes and alternative splicing events for biomarker discovery and disease diagnostics. The field of transcriptomics is currently being revolutionized by high throughput DNA sequencing methodologies to map, characterize, and quantify the transcriptome. Methods: In an effort to understand the merits and limitations of each of these tools, we undertook a study of the transcriptome in sickle cell disease, a monogenic disease comparing the Affymetrix Human Exon 1.0 ST microarray (Exon array) and Illuminas deep sequencing technology (RNA-seq) on whole blood clinical specimens. Results: Analysis indicated a strong concordance (R = 0.64) between Exon array and RNA-seq data at both gene level and exon level transcript expression. The magnitude of differential expression was found to be generally higher in RNA-seq than in the Exon microarrays. We also demonstrate for the first time the ability of RNA-seq technology to discover novel transcript variants and differential expression in previously unannotated genomic regions in sickle cell disease. In addition to detecting expression level changes, RNA-seq technology was also able to identify sequence variation in the expressed transcripts. Conclusions: Our findings suggest that microarrays remain useful and accurate for transcriptomic analysis of clinical samples with low input requirements, while RNA-seq technology complements and extends microarray measurements for novel discoveries.

KW - Clinical genomics

KW - Exon arrays

KW - RNA-Seq

KW - Sickle cell disease

KW - Transcriptome

UR - http://www.scopus.com/inward/record.url?scp=84862996504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862996504&partnerID=8YFLogxK

U2 - 10.1186/1755-8794-5-28

DO - 10.1186/1755-8794-5-28

M3 - Article

C2 - 22747986

AN - SCOPUS:84862996504

VL - 5

JO - BMC Medical Genomics

JF - BMC Medical Genomics

SN - 1755-8794

M1 - 28

ER -